135 related articles for article (PubMed ID: 20224821)
1. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.
Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA
PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821
[TBL] [Abstract][Full Text] [Related]
2. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process.
Martínez-Poveda B; Quesada AR; Medina MA
Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212
[TBL] [Abstract][Full Text] [Related]
3. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP
Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112
[TBL] [Abstract][Full Text] [Related]
4. Hyperforin: more than an antidepressant bioactive compound?
Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
[TBL] [Abstract][Full Text] [Related]
5. Hyperforin.
Beerhues L
Phytochemistry; 2006 Oct; 67(20):2201-7. PubMed ID: 16973193
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent.
Lorusso G; Vannini N; Sogno I; Generoso L; Garbisa S; Noonan DM; Albini A
Eur J Cancer; 2009 May; 45(8):1474-84. PubMed ID: 19223175
[TBL] [Abstract][Full Text] [Related]
7. Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore.
Leuner K; Heiser JH; Derksen S; Mladenov MI; Fehske CJ; Schubert R; Gollasch M; Schneider G; Harteneck C; Chatterjee SS; Müller WE
Mol Pharmacol; 2010 Mar; 77(3):368-77. PubMed ID: 20008516
[TBL] [Abstract][Full Text] [Related]
8. Hyperforin acts as an angiogenesis inhibitor.
Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC
Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199
[TBL] [Abstract][Full Text] [Related]
9. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
10. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
[TBL] [Abstract][Full Text] [Related]
11. Hyperforin and its analogues inhibit CYP3A4 enzyme activity.
Lee JY; Duke RK; Tran VH; Hook JM; Duke CC
Phytochemistry; 2006 Dec; 67(23):2550-60. PubMed ID: 17083953
[TBL] [Abstract][Full Text] [Related]
12. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
13. Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives.
Pia Schiavone BI; Verotta L; Rosato A; Marilena M; Gibbons S; Bombardelli E; Franchini C; Corbo F
Anticancer Agents Med Chem; 2014; 14(10):1397-1401. PubMed ID: 25173557
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of hyperforin analogues for inhibition of 5-lipoxygenase.
Feisst C; Albert D; Verotta L; Werz O
Med Chem; 2005 May; 1(3):287-91. PubMed ID: 16787324
[TBL] [Abstract][Full Text] [Related]
15. Hyperforin, a new lead compound against the progression of cancer and leukemia?
Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
[TBL] [Abstract][Full Text] [Related]
16. In vitro antimalarial activity of hyperforin, a prenylated acylphloroglucinol. A structure-activity study.
Verotta L; Appendino G; Bombardelli E; Brun R
Bioorg Med Chem Lett; 2007 Mar; 17(6):1544-8. PubMed ID: 17234416
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort.
Jakobs D; Hage-Hülsmann A; Prenner L; Kolb C; Weiser D; Häberlein H
J Pharm Pharmacol; 2013 Jun; 65(6):907-15. PubMed ID: 23647684
[TBL] [Abstract][Full Text] [Related]
18. Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels.
Leuner K; Kazanski V; Müller M; Essin K; Henke B; Gollasch M; Harteneck C; Müller WE
FASEB J; 2007 Dec; 21(14):4101-11. PubMed ID: 17666455
[TBL] [Abstract][Full Text] [Related]
19. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S
Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950
[TBL] [Abstract][Full Text] [Related]
20. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin.
Tadros MG; Mohamed MR; Youssef AM; Sabry GM; Sabry NA; Khalifa AE
Behav Brain Res; 2009 May; 199(2):334-9. PubMed ID: 19136030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
